These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7589181)

  • 1. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
    Kaur S; Starr MS
    Eur J Pharmacol; 1995 Jul; 280(2):159-66. PubMed ID: 7589181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor effects of lamotrigine in naive and dopamine-depleted mice.
    Kaur S; Starr M
    Eur J Pharmacol; 1996 May; 304(1-3):1-6. PubMed ID: 8813577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice.
    Starr MS; Starr BS
    Psychopharmacology (Berl); 1994 Apr; 114(3):469-76. PubMed ID: 7855205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
    Brooks S; Kaur S; Starr BS; Starr MS
    J Neural Transm (Vienna); 1996; 103(6):737-48. PubMed ID: 8836935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse.
    Starr MS; Starr BS
    Eur J Pharmacol; 1993 Dec; 250(2):239-46. PubMed ID: 7906652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
    Starr BS; Starr MS; Kilpatrick IC
    Neuroscience; 1987 Jul; 22(1):179-88. PubMed ID: 2957609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of dopamine-dependent locomotion by clonidine in reserpine-treated mice is restricted to D2 agonists.
    Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):133-42. PubMed ID: 7710665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors.
    Starr MS; Starr BS
    Eur J Pharmacol; 1995 Apr; 277(2-3):151-8. PubMed ID: 7493603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist.
    Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1995; 9(1):31-43. PubMed ID: 7605588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
    Kaur S; Starr MS; Starr BS
    J Neural Transm Park Dis Dement Sect; 1994; 8(1-2):107-16. PubMed ID: 7893372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do NMDA receptor-mediated changes in motor behaviour involve nitric oxide?
    Starr MS; Starr BS
    Eur J Pharmacol; 1995 Jan; 272(2-3):211-7. PubMed ID: 7713165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents.
    Popoli P; Giménez-Llort L; Pezzola A; Reggio R; Martínez E; Fuxe K; Ferré S
    Neurosci Lett; 1996 Nov; 218(3):209-13. PubMed ID: 8945765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
    Fox SH; Brotchie JM
    Eur J Pharmacol; 2000 Jun; 398(1):59-64. PubMed ID: 10856448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists.
    Simola N; Fenu S; Baraldi PG; Tabrizi MA; Morelli M
    Synapse; 2008 May; 62(5):345-51. PubMed ID: 18297692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
    Andringa G; Vermeulen RJ; Drukarch B; Stoof JC; Cools AR
    Adv Pharmacol; 1998; 42():792-5. PubMed ID: 9328017
    [No Abstract]   [Full Text] [Related]  

  • 18. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Ni L
    J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
    Huang KX; Bergstrom DA; Ruskin DN; Walters JR
    Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
    Boyce S; Rupniak NM; Steventon MJ; Iversen SD
    Neurology; 1990 Jun; 40(6):927-33. PubMed ID: 2140595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.